title: [The expression assessment of the estrogen, progesterone and HER2 receptors in selected malignant tumors of the salivary glands].
abstract: BACKGROUND
  The incidence of the malignant tumors of the salivary glands is relatelively low. However, rapid locoregional progression, distant metastases occurrence and high local recurrence rate occurring despite radical surgical treatment, significantly affect the outcome. Malignant tumors of the salivary glands are characterized by low radiosensitivity and poor response to systemic therapy. Therefore there is a need for new targeted therapies which may improve the prognosis. In some aspects, malignant tumors of the salivary glands are similar to breast cancers. Efficacy of hormonal replacement therapy and the treatment with the monoclonal antibody (trastuzumab) in the treatment of breast cancer is well known and confirmed. Criterion determining the qualification for treatment is the presence of hormone receptors and HER2 receptors in the tumor.
  
  
  OBJECTIVE
  The aim of this study was to evaluate the expression of estrogen receptor, progesterone receptor and HER2 in selected salivary gland malignancies.
  
  
  METHODS
  Study group consisted of 51 patients with the salivary glands cancer. In the study group there were 42 tumors in the parotid gland, 7 tumors of the submandibular gland, 1 in the mucosa of the cheek and 1 tumor in the tongue. Histologically material comprised of muco-epidermoid carcinoma (10), adenoid-cystic carcinoma (8), salivary duct (7), adenocarcinoma (6), squamous cell carcinoma (6), mioepithelial carcinoma (5) and other (9). In all cases immunohistochemical analysis of the estrogen receptor, progesterone receptor and HER2 receptor was performed.
  
  
  RESULTS
  The expression of the estrogen receptor was found in 18% of tumors (9 patients). The expression of the progesterone receptor was found in 20% (10 patients). HER2 expression was found in 10% of tumors and was related to only one histological type of tumor - salivary duct carcinoma.
  
  
  CONCLUSIONS
  HER2 expression in malignant tumors of the salivary glands, especially in salivary duct carcinoma may be of use in future implementation of new targeted therapies based on monoclonal antibodies.
authors.affiliation: Klinika Chirurgii Głowy, Szyi i Onkologii Laryngologicznej. Uniwersytet Medyczny im. Karola Marcinkowskiego, Kierownik: prof. dr hab. Wojciech Golusiński, Poznań, Poland; Wielkopolskie Centrum Onkologii im. Marii Skłodowskiej-Curie, Kierownik: prof. dr hab. Julian Malicki, Poznań, Poland.
authors.forename: Wojciech
authors.initials: W
authors.lastname: Golusiński
authors.forename: Anna
authors.initials: A
authors.lastname: Wegner
authors.forename: Paweł
authors.initials: P
authors.lastname: Trzeciak
authors.forename: Paweł
authors.initials: P
authors.lastname: Golusiński
authors.forename: Marcin
authors.initials: M
authors.lastname: Sówka
authors.forename: Andrzej
authors.initials: A
authors.lastname: Kopczyński
authors.forename: Małgorzata
authors.initials: M
authors.lastname: Bromboszcz
authors.forename: Andrzej
authors.initials: A
authors.lastname: Marszałek
mesh_terms: D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000378:metabolism*; D002277:Carcinoma / Q000378:metabolism* / Q000473:pathology; D005260:Female; D006801:Humans; D007120:Immunochemistry; D008297:Male; D008875:Middle Aged; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D011960:Receptors, Estrogen / Q000378:metabolism*; D011980:Receptors, Progesterone / Q000378:metabolism*; D012468:Salivary Gland Neoplasms / Q000209:etiology / Q000378:metabolism* / Q000473:pathology; D012469:Salivary Glands / Q000473:pathology; D000068878:Trastuzumab
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D014408:Biomarkers, Tumor; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D000068878:Trastuzumab
keywords: Ductal cancer; Estrogen receptor; HER2 receptor; Progesteron receptor; Salivary gland cancer; nowotwory złośliwe ślinianek; rak przewodowy ślinianki; receptor HER2; receptor estrogenowy; receptor progesteronowy